{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:50:45Z","timestamp":1792547445058,"version":"4.5.0"},"reference-count":129,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.jconrel.2011.09.069","type":"journal-article","created":{"date-parts":[[2011,9,17]],"date-time":"2011-09-17T03:15:20Z","timestamp":1316229320000},"page":"4-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":785,"title":["Impact of albumin on drug delivery \u2014 New applications on the horizon"],"prefix":"10.1016","volume":"157","author":[{"given":"Bakheet","family":"Elsadek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Kratz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jconrel.2011.09.069_bb0005","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jmb.2008.06.016","article-title":"Crystallographic analysis of human serum albumin complexed with 4Z,15E-bilirubin-IXalpha","volume":"381","author":"Zunszain","year":"2008","journal-title":"J. Mol. Biol."},{"issue":"2","key":"10.1016\/j.jconrel.2011.09.069_bb0010","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jmb.2005.11.060","article-title":"Purification, properties and extended solution structure of the complex formed between human immunoglobulin A1 and human serum albumin by scattering and ultracentrifugation","volume":"356","author":"Almogren","year":"2006","journal-title":"J. Mol. Biol."},{"issue":"17","key":"10.1016\/j.jconrel.2011.09.069_bb0015","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.2165\/00003495-200767170-00007","article-title":"Defining the role of insulin detemir in Basal insulin therapy","volume":"67","author":"Morales","year":"2007","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.jconrel.2011.09.069_bb0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1089\/dia.2009.0127","article-title":"The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes \u2014 a comprehensive review","volume":"12","author":"Garg","year":"2010","journal-title":"Diabetes Technol. Ther."},{"issue":"31","key":"10.1016\/j.jconrel.2011.09.069_bb0025","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.jconrel.2011.09.069_bb0030","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2008.18.5397","article-title":"Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer","volume":"27","author":"Gradishar","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.jconrel.2011.09.069_bb0035","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.addr.2007.08.044","article-title":"Protein nanoparticles as drug carriers in clinical medicine","volume":"60","author":"Hawkins","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.jconrel.2011.09.069_bb0040","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1593\/tlo.09109","article-title":"SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients","volume":"2","author":"Desai","year":"2009","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.jconrel.2011.09.069_bb0650","series-title":"American Society of Clinical Oncology (ASCO) annual meeting","article-title":"SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I\/II study","author":"Von Hoff","year":"2009"},{"issue":"1 Pt 2","key":"10.1016\/j.jconrel.2011.09.069_bb0050","first-page":"H246","article-title":"gp60 is an albumin-binding glycoprotein expressed by continuous endothelium involved in albumin transcytosis","volume":"262","author":"Schnitzer","year":"1992","journal-title":"Am. J. Physiol."},{"issue":"41","key":"10.1016\/j.jconrel.2011.09.069_bb0055","doi-asserted-by":"crossref","first-page":"25968","DOI":"10.1074\/jbc.272.41.25968","article-title":"Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosine kinase-dependent pathway","volume":"272","author":"Tiruppathi","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.jconrel.2011.09.069_bb0060","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1021\/nn9012274","article-title":"Size and dynamics of caveolae studied using nanoparticles in living endothelial cells","volume":"3","author":"Wang","year":"2009","journal-title":"ACS Nano"},{"issue":"6","key":"10.1016\/j.jconrel.2011.09.069_bb0065","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1016\/S0021-9258(17)43194-2","article-title":"Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture","volume":"259","author":"Sage","year":"1984","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.jconrel.2011.09.069_bb0070","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s10555-008-9146-7","article-title":"The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host","volume":"27","author":"Podhajcer","year":"2008","journal-title":"Cancer Metastasis Rev."},{"issue":"4","key":"10.1016\/j.jconrel.2011.09.069_bb0075","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1593\/neo.101490","article-title":"Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases","volume":"13","author":"Volk","year":"2011","journal-title":"Neoplasia"},{"issue":"3","key":"10.1016\/j.jconrel.2011.09.069_bb0080","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1248\/yakushi.128.323","article-title":"Application of radiometallic compounds for medical diagnosis and therapy","volume":"128","author":"Saji","year":"2008","journal-title":"Yakugaku Zasshi"},{"issue":"4","key":"10.1016\/j.jconrel.2011.09.069_bb0085","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1620\/tjem.211.379","article-title":"On-site preparation of technetium-99m labeled human serum albumin for clinical application","volume":"211","author":"Wang","year":"2007","journal-title":"Tohoku J. Exp. Med."},{"issue":"7","key":"10.1016\/j.jconrel.2011.09.069_bb0090","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/00003072-199807000-00006","article-title":"Usefulness of Technetium-99m human serum albumin lymphoscintigraphy in chyluria","volume":"23","author":"Nishiyama","year":"1998","journal-title":"Clin. Nucl. Med."},{"issue":"4","key":"10.1016\/j.jconrel.2011.09.069_bb0095","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/00003072-200104000-00002","article-title":"Lymphoscintigraphic sentinel node imaging and gamma probe detection in breast cancer with Tc-99m nanocolloidal albumin: results of an optimized protocol","volume":"26","author":"Rink","year":"2001","journal-title":"Clin. Nucl. Med."},{"issue":"6","key":"10.1016\/j.jconrel.2011.09.069_bb0100","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.ejcts.2010.01.012","article-title":"Intra-operative sentinel lymph node identification using a novel receptor-binding agent (technetium-99m neomannosyl human serum albumin, 99mTc-MSA) in stage I non-small cell lung cancer","volume":"37","author":"Kim","year":"2010","journal-title":"Eur. J. Cardiothorac. Surg."},{"issue":"5","key":"10.1016\/j.jconrel.2011.09.069_bb0105","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.athoracsur.2011.01.016","article-title":"Sentinel node identification using Technetium-99m neomannosyl human serum albumin in esophageal cancer","volume":"91","author":"Kim","year":"2011","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.jconrel.2011.09.069_bb0110","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2385-5-7","article-title":"Relationship of 99m technetium labelled macroaggregated albumin (99mTc-MAA) uptake by colorectal liver metastases to response following Selective Internal Radiation Therapy (SIRT)","volume":"5","author":"Dhabuwala","year":"2005","journal-title":"BMC Nucl. Med."},{"issue":"3","key":"10.1016\/j.jconrel.2011.09.069_bb0115","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s002590000418","article-title":"Assessment of leg oedema by dynamic lymphoscintigraphy with intradermal injection of technetium-99m human serum albumin and load produced by standing","volume":"28","author":"Suga","year":"2001","journal-title":"Eur. J. Nucl. Med."},{"issue":"8","key":"10.1016\/j.jconrel.2011.09.069_bb0120","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/ki.2009.271","article-title":"Pitfalls of technetium-99m-labeled human serum albumin scintigraphy for protein-losing enteropathy","volume":"76","author":"Hsu","year":"2009","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.jconrel.2011.09.069_bb0125","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00006231-200103000-00008","article-title":"99Tc(m) nanocolloid scintigraphy: a reliable way to detect active joint disease in patients with peripheral joint pain","volume":"22","author":"Adams","year":"2001","journal-title":"Nucl. Med. Commun."},{"issue":"3","key":"10.1016\/j.jconrel.2011.09.069_bb0130","first-page":"245","article-title":"Lymphoscintigraphy with intraoperative gamma probe sentinel node detection: clinical impact in patients with head and neck melanomas","volume":"49","author":"Maccauro","year":"2005","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"issue":"9","key":"10.1016\/j.jconrel.2011.09.069_bb0135","first-page":"1500","article-title":"Evaluation of mammary lymphoscintigraphy by a single intratumoral injection for sentinel node identification","volume":"41","author":"Valdes-Olmos","year":"2000","journal-title":"J. Nucl. Med."},{"issue":"3","key":"10.1016\/j.jconrel.2011.09.069_bb0140","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.2349\/biij.2.3.e43","article-title":"Trans-arterial hepatic radioembolisation of yttrium-90 microspheres","volume":"2","author":"Murthy","year":"2006","journal-title":"Biomed. Imaging Intervention J."},{"issue":"4","key":"10.1016\/j.jconrel.2011.09.069_bb0655","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.eururo.2011.03.024","article-title":"Intraoperative laparoscopic fluorescence guidance to the sentinel lymph node in prostate cancer patients: clinical proof of concept of an integrated functional imaging approach using a multimodal tracer","volume":"60","author":"van der Poel","year":"2011","journal-title":"Eur. Urol."},{"issue":"7","key":"10.1016\/j.jconrel.2011.09.069_bb0150","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1021\/jm9905864","article-title":"A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy","volume":"43","author":"Kratz","year":"2000","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.jconrel.2011.09.069_bb0155","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s10637-008-9208-2","article-title":"INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model","volume":"28","author":"Graeser","year":"2009","journal-title":"Invest. New Drugs"},{"issue":"25","key":"10.1016\/j.jconrel.2011.09.069_bb0160","doi-asserted-by":"crossref","first-page":"5523","DOI":"10.1021\/jm020276c","article-title":"Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound","volume":"45","author":"Kratz","year":"2002","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.jconrel.2011.09.069_bb0165","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1158\/1078-0432.CCR-06-2776","article-title":"Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin","volume":"13","author":"Unger","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2011.09.069_bb0170","article-title":"Combination therapy with the albumin-binding prodrug of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves tolerability in an ovarian A2780 xenograft model","author":"Kratz","year":"2011","journal-title":"Invest. New Drugs"},{"issue":"5","key":"10.1016\/j.jconrel.2011.09.069_bb0175","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1463-1326.2011.01357.x","article-title":"An overview of once-weekly GLP-1 receptor agonists \u2014 available efficacy and safety data and perspectives for the future","volume":"13","author":"Madsbad","year":"2011","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"10.1016\/j.jconrel.2011.09.069_bb0180","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1210\/me.2002-0306","article-title":"Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis","volume":"17","author":"Drucker","year":"2003","journal-title":"Mol. Endocrinol."},{"issue":"4","key":"10.1016\/j.jconrel.2011.09.069_bb0185","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1053\/j.gastro.2008.01.017","article-title":"An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis","volume":"134","author":"Baggio","year":"2008","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jconrel.2011.09.069_bb0190","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2337\/diabetes.52.3.751","article-title":"Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo","volume":"52","author":"Kim","year":"2003","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.jconrel.2011.09.069_bb0195","first-page":"1245","article-title":"CJC-1131","volume":"4","author":"Giannoukakis","year":"2003","journal-title":"ConjuChem. Curr. Opin. Investig. Drugs"},{"issue":"10","key":"10.1016\/j.jconrel.2011.09.069_bb0200","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1517\/14712598.2010.521494","article-title":"Albinterferon-alpha 2b: a new treatment option for hepatitis C","volume":"10","author":"Flisiak","year":"2010","journal-title":"Expert Opin. Biol. Ther."},{"issue":"4","key":"10.1016\/j.jconrel.2011.09.069_bb0205","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1053\/j.gastro.2010.06.062","article-title":"Albinterferon Alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3","volume":"139","author":"Nelson","year":"2010","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jconrel.2011.09.069_bb0210","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1053\/j.gastro.2010.06.066","article-title":"Albinterferon Alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 1","volume":"139","author":"Zeuzem","year":"2010","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jconrel.2011.09.069_bb0215","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1177\/0091270010372626","article-title":"Pharmacokinetics of 5-aminofluorescein-albumin, a novel fluorescence marker of brain tumors during surgery","volume":"51","author":"Ding","year":"2011","journal-title":"J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.jconrel.2011.09.069_bb0220","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3171\/jns.1948.5.4.0392","article-title":"The clinical use of fluorescein in neurosurgery; the localization of brain tumors","volume":"5","author":"Moore","year":"1948","journal-title":"J. Neurosurg."},{"issue":"3","key":"10.1016\/j.jconrel.2011.09.069_bb0225","first-page":"53","article-title":"Intraoperative fluorescence staining of malignant brain tumors using 5-aminofluorescein-labeled albumin","volume":"64","author":"Kremer","year":"2009","journal-title":"Neurosurgery"},{"issue":"5","key":"10.1016\/j.jconrel.2011.09.069_bb0230","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/01616412.2000.11740705","article-title":"Laser-induced fluorescence detection of malignant gliomas using fluorescein-labeled serum albumin: experimental and preliminary clinical results","volume":"22","author":"Kremer","year":"2000","journal-title":"Neurol. Res."},{"key":"10.1016\/j.jconrel.2011.09.069_bb0235","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1172\/JCI104594","article-title":"Studies of I-131-albumin catabolism and distribution in normal young male adults","volume":"41","author":"Beeken","year":"1962","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.jconrel.2011.09.069_bb0240","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S1470-2045(06)70665-9","article-title":"Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial","volume":"7","author":"Stummer","year":"2006","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.jconrel.2011.09.069_bb0245","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10014-007-0223-3","article-title":"Fluorescence-guided resection of metastatic brain tumors using a 5-aminolevulinic acid-induced protoporphyrin IX: pathological study","volume":"24","author":"Utsuki","year":"2007","journal-title":"Brain Tumor Pathol."},{"issue":"5","key":"10.1016\/j.jconrel.2011.09.069_bb0250","doi-asserted-by":"crossref","first-page":"E1101","DOI":"10.1227\/01.neu.0000303209.38360.e6","article-title":"Fluorescence of non-neoplastic, magnetic resonance imaging-enhancing tissue by 5-aminolevulinic acid: case report","volume":"61","author":"Miyatake","year":"2007","journal-title":"Neurosurgery"},{"issue":"3","key":"10.1016\/j.jconrel.2011.09.069_bb0255","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1084\/jem.20021829","article-title":"The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan","volume":"197","author":"Chaudhury","year":"2003","journal-title":"J. Exp. Med."},{"issue":"15","key":"10.1016\/j.jconrel.2011.09.069_bb0260","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1021\/bi052628y","article-title":"Albumin binding to FcRn: distinct from the FcRn\u2013IgG interaction","volume":"45","author":"Chaudhury","year":"2006","journal-title":"Biochemistry"},{"issue":"38","key":"10.1016\/j.jconrel.2011.09.069_bb0265","doi-asserted-by":"crossref","first-page":"35035","DOI":"10.1074\/jbc.M205854200","article-title":"Albumin binding as a general strategy for improving the pharmacokinetics of proteins","volume":"277","author":"Dennis","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.jconrel.2011.09.069_bb0270","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1158\/0008-5472.CAN-06-2531","article-title":"Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent","volume":"67","author":"Dennis","year":"2007","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.jconrel.2011.09.069_bb0275","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.jconrel.2011.09.069_bb0280","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","article-title":"Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group","volume":"23","author":"Marty","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.jconrel.2011.09.069_bb0285","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3747\/co.v16i4.469","article-title":"The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer","volume":"16","author":"Dent","year":"2009","journal-title":"Curr. Oncol."},{"issue":"5","key":"10.1016\/j.jconrel.2011.09.069_bb0290","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.jconrel.2011.09.069_bb0295","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/protein\/gzn028","article-title":"Engineering of a femtomolar affinity binding protein to human serum albumin","volume":"21","author":"Jonsson","year":"2008","journal-title":"Protein Eng. Des. Sel."},{"issue":"12","key":"10.1016\/j.jconrel.2011.09.069_bb0300","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1158\/1078-0432.CCR-07-4076","article-title":"Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging","volume":"14","author":"Lee","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.jconrel.2011.09.069_bb0305","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2310\/7290.2010.00018","article-title":"Quantitative analysis of Her2 receptor expression in vivo by near-infrared optical imaging","volume":"9","author":"Chernomordik","year":"2010","journal-title":"Mol. Imaging"},{"issue":"3","key":"10.1016\/j.jconrel.2011.09.069_bb0310","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1021\/bc100432h","article-title":"Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting","volume":"22","author":"Hoppmann","year":"2011","journal-title":"Bioconjug. Chem."},{"issue":"2","key":"10.1016\/j.jconrel.2011.09.069_bb0315","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s00259-009-1268-9","article-title":"(186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours","volume":"37","author":"Orlova","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"6","key":"10.1016\/j.jconrel.2011.09.069_bb0320","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1158\/0008-5472.CAN-06-1630","article-title":"Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule","volume":"67","author":"Tolmachev","year":"2007","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.jconrel.2011.09.069_bb0325","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0923-2494(98)80011-4","article-title":"Recent advances in the large-scale production of antibody fragments using lower eukaryotic microorganisms","volume":"149","author":"Frenken","year":"1998","journal-title":"Res. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2011.09.069_bb0330","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0168-1656(99)00228-X","article-title":"Isolation of antigen specific llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae","volume":"78","author":"Frenken","year":"2000","journal-title":"J. Biotechnol."},{"issue":"6","key":"10.1016\/j.jconrel.2011.09.069_bb0335","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/art.21827","article-title":"Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis","volume":"54","author":"Coppieters","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.jconrel.2011.09.069_bb0340","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.4049\/jimmunol.170.9.4793","article-title":"Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis","volume":"170","author":"Wunder","year":"2003","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.jconrel.2011.09.069_bb0345","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/ijc.10212","article-title":"Efficient tumor targeting by single-domain antibody fragments of camels","volume":"98","author":"Cortez-Retamozo","year":"2002","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.jconrel.2011.09.069_bb0350","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1158\/0008-5472.CAN-03-3935","article-title":"Efficient cancer therapy with a nanobody-based conjugate","volume":"64","author":"Cortez-Retamozo","year":"2004","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.jconrel.2011.09.069_bb0355","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1158\/1535-7163.MCT-07-2384","article-title":"Improved tumor targeting of anti-epidermal growth factor receptor nanobodies through albumin binding: taking advantage of modular nanobody technology","volume":"7","author":"Tijink","year":"2008","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.jconrel.2011.09.069_bb0360","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/protein\/gzm067","article-title":"Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs","volume":"21","author":"Holt","year":"2008","journal-title":"Protein Eng. Des. Sel."},{"issue":"4","key":"10.1016\/j.jconrel.2011.09.069_bb0365","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/protein\/gzp091","article-title":"Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon","volume":"23","author":"Walker","year":"2010","journal-title":"Protein Eng. Des. Sel."},{"issue":"23","key":"10.1016\/j.jconrel.2011.09.069_bb0370","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJM200106073442306","article-title":"AIDS\u2014the first 20 years","volume":"344","author":"Sepkowitz","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jconrel.2011.09.069_bb0375","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1365-2796.2007.01910.x","article-title":"The first postmodern pandemic: 25 years of HIV\/AIDS","volume":"263","author":"Kallings","year":"2008","journal-title":"J. Intern. Med."},{"issue":"Suppl 2","key":"10.1016\/j.jconrel.2011.09.069_bb0660","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1136\/sti.2010.044784","article-title":"Modelling HIV epidemics in the antiretroviral era: the UNAIDS estimation and projection package 2009","volume":"86","author":"Brown","year":"2010","journal-title":"Sex. Transm. Infect."},{"issue":"2","key":"10.1016\/j.jconrel.2011.09.069_bb0385","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11262-007-0098-8","article-title":"Transmembrane protein polymorphisms and resistance to T-20 (Enfuvirtide, Fuzeon) in HIV-1 infected therapy-naive seroconverters and AIDS patients under HAART-T-20 therapy","volume":"35","author":"Morozov","year":"2007","journal-title":"Virus Genes"},{"issue":"20","key":"10.1016\/j.jconrel.2011.09.069_bb0665","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.2174\/092986706777935069","article-title":"A novel antiretroviral class (fusion inhibitors) in the management of HIV infection. Present features and future perspectives of enfuvirtide (T-20)","volume":"13","author":"Manfredi","year":"2006","journal-title":"Curr. Med. Chem."},{"issue":"49","key":"10.1016\/j.jconrel.2011.09.069_bb0395","doi-asserted-by":"crossref","first-page":"34045","DOI":"10.1074\/jbc.M805536200","article-title":"Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy\/Liv mice","volume":"283","author":"Stoddart","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.jconrel.2011.09.069_bb0400","doi-asserted-by":"crossref","first-page":"e655","DOI":"10.1371\/journal.pone.0000655","article-title":"Validation of the SCID-hu Thy\/Liv mouse model with four classes of licensed antiretrovirals","volume":"2","author":"Stoddart","year":"2007","journal-title":"PLoS One"},{"issue":"18","key":"10.1016\/j.jconrel.2011.09.069_bb0405","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1056\/NEJMra032395","article-title":"Where does HIV live?","volume":"350","author":"Stebbing","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jconrel.2011.09.069_bb0410","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/(SICI)1520-6017(200003)89:3<297::AID-JPS2>3.0.CO;2-P","article-title":"Lymphatic transport of proteins after subcutaneous administration","volume":"89","author":"Porter","year":"2000","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2011.09.069_bb0415","first-page":"5","article-title":"Whole body capillary exchange of albumin","volume":"603","author":"Bent-Hansen","year":"1991","journal-title":"Acta Physiol. Scand. Suppl."},{"issue":"3","key":"10.1016\/j.jconrel.2011.09.069_bb0420","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10989-006-9033-4","article-title":"Identification and characterization of novel lipophilic antimicrobial peptides derived from naturally occurring proteins","volume":"12","author":"Hussain","year":"2006","journal-title":"Int. J. Pept. Res. Ther."},{"issue":"4","key":"10.1016\/j.jconrel.2011.09.069_bb0425","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1517\/13543784.11.4.545","article-title":"Therapies in development for community-acquired pneumonia","volume":"11","author":"Blasi","year":"2002","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"3","key":"10.1016\/j.jconrel.2011.09.069_bb0430","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10989-006-9028-1","article-title":"Fat-free albumin as a novel drug delivery system","volume":"12","author":"Hussain","year":"2006","journal-title":"Int. J. Pept. Res. Ther."},{"issue":"Suppl 1","key":"10.1016\/j.jconrel.2011.09.069_bb0435","first-page":"E44","article-title":"Novel drug delivery system for lipophilic therapeutics of small molecule, peptide-based and protein drugs","volume":"22","author":"Hussain","year":"2010","journal-title":"Chirality"},{"issue":"12","key":"10.1016\/j.jconrel.2011.09.069_bb0440","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1128\/AAC.35.12.2505","article-title":"Effect of protein binding of daptomycin on MIC and antibacterial activity","volume":"35","author":"Lee","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.jconrel.2011.09.069_bb0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cmmi.265","article-title":"Classification and basic properties of contrast agents for magnetic resonance imaging","volume":"4","author":"Geraldes","year":"2009","journal-title":"Contrast Media Mol. Imaging"},{"issue":"7","key":"10.1016\/j.jconrel.2011.09.069_bb0450","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1021\/ar800220p","article-title":"Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action","volume":"42","author":"Caravan","year":"2009","journal-title":"Acc. Chem. Res."},{"issue":"2","key":"10.1016\/j.jconrel.2011.09.069_bb0455","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1148\/radiology.207.2.9577506","article-title":"MS-325: albumin-targeted contrast agent for MR angiography","volume":"207","author":"Lauffer","year":"1998","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.jconrel.2011.09.069_bb0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/vhrm.2008.04.01.1","article-title":"Gadofosveset-enhanced magnetic resonance angiography","volume":"4","author":"Goyen","year":"2008","journal-title":"Vasc. Health Risk Manag."},{"issue":"12 Pt 1","key":"10.1016\/j.jconrel.2011.09.069_bb0465","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2011.09.069_bb0470","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s00330-009-1530-3","article-title":"Human brain tumor imaging with a protein-binding MR contrast agent: initial experience","volume":"20","author":"Essig","year":"2010","journal-title":"Eur. Radiol."},{"issue":"3","key":"10.1016\/j.jconrel.2011.09.069_bb0475","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/SLA.0b013e31820b01f1","article-title":"Accuracy of gadofosveset-enhanced MRI for nodal staging and restaging in rectal cancer","volume":"253","author":"Lambregts","year":"2011","journal-title":"Ann. Surg."},{"issue":"1","key":"10.1016\/j.jconrel.2011.09.069_bb0480","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11604-010-0513-2","article-title":"Diffusion magnetic resonance imaging with gadofosveset trisodium as a negative contrast agent for lymph node metastases assessment","volume":"29","author":"Yamashita","year":"2011","journal-title":"Jpn. J. Radiol."},{"issue":"7","key":"10.1016\/j.jconrel.2011.09.069_bb0485","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0730-725X(03)00100-0","article-title":"MRI of blood volume with MS 325 in experimental choroidal melanoma","volume":"21","author":"Krause","year":"2003","journal-title":"Magn. Reson. Imaging"},{"issue":"6","key":"10.1016\/j.jconrel.2011.09.069_bb0490","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.2214\/ajr.179.6.1791567","article-title":"Interstitial MR lymphography with MS-325: characterization of normal and tumor-invaded lymph nodes in a rabbit model","volume":"179","author":"Herborn","year":"2002","journal-title":"AJR Am. J. Roentgenol."},{"issue":"3","key":"10.1016\/j.jconrel.2011.09.069_bb0495","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/jmri.1179","article-title":"MRI assessment of microvascular characteristics in experimental breast tumors using a new blood pool contrast agent (MS-325) with correlations to histopathology","volume":"14","author":"Turetschek","year":"2001","journal-title":"J. Magn. Reson. Imaging"},{"issue":"3","key":"10.1016\/j.jconrel.2011.09.069_bb0500","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10334-008-0106-6","article-title":"Tumor microvasculature observed using different contrast agents: a comparison between Gd-DTPA-Albumin and B-22956\/1 in an experimental model of mammary carcinoma","volume":"21","author":"Boschi","year":"2008","journal-title":"MAGMA"},{"issue":"11","key":"10.1016\/j.jconrel.2011.09.069_bb0505","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1111\/j.1349-7006.2007.00602.x","article-title":"Targeted optical fluorescence imaging of human ovarian adenocarcinoma using a galactosyl serum albumin-conjugated fluorophore","volume":"98","author":"Gunn","year":"2007","journal-title":"Cancer Sci."},{"issue":"7","key":"10.1016\/j.jconrel.2011.09.069_bb0510","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1593\/neo.06268","article-title":"In vivo spectral fluorescence imaging of submillimeter peritoneal cancer implants using a lectin-targeted optical agent","volume":"8","author":"Hama","year":"2006","journal-title":"Neoplasia"},{"issue":"21","key":"10.1016\/j.jconrel.2011.09.069_bb0515","doi-asserted-by":"crossref","first-page":"6335","DOI":"10.1158\/1078-0432.CCR-07-1004","article-title":"A self-quenched galactosamine-serum albumin-rhodamineX conjugate: a \u201csmart\u201d fluorescent molecular imaging probe synthesized with clinically applicable material for detecting peritoneal ovarian cancer metastases","volume":"13","author":"Hama","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.jconrel.2011.09.069_bb0520","doi-asserted-by":"crossref","first-page":"051501","DOI":"10.1117\/1.2779351","article-title":"d-galactose receptor-targeted in vivo spectral fluorescence imaging of peritoneal metastasis using galactosamin-conjugated serum albumin-rhodamine green","volume":"12","author":"Hama","year":"2007","journal-title":"J. Biomed. Opt."},{"issue":"8","key":"10.1016\/j.jconrel.2011.09.069_bb0525","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1023\/A:1015926119947","article-title":"Endothelium-derived nitric oxide: pharmacology and relationship to the actions of organic nitrate esters","volume":"6","author":"Ignarro","year":"1989","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.jconrel.2011.09.069_bb0530","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1476-5381.1986.tb10218.x","article-title":"Endothelium-dependent inhibition of platelet aggregation","volume":"88","author":"Azuma","year":"1986","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.jconrel.2011.09.069_bb0535","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/0166-2236(91)90022-M","article-title":"Glutamate, nitric oxide and cell\u2013cell signalling in the nervous system","volume":"14","author":"Garthwaite","year":"1991","journal-title":"Trends Neurosci."},{"issue":"24","key":"10.1016\/j.jconrel.2011.09.069_bb0540","doi-asserted-by":"crossref","first-page":"8706","DOI":"10.1021\/bi00424a003","article-title":"Macrophage oxidation of l-arginine to nitrite and nitrate: nitric oxide is an intermediate","volume":"27","author":"Marletta","year":"1988","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.jconrel.2011.09.069_bb0545","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/hh0102.102330","article-title":"Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview","volume":"90","author":"Ignarro","year":"2002","journal-title":"Circ. Res."},{"issue":"7","key":"10.1016\/j.jconrel.2011.09.069_bb0550","first-page":"817","article-title":"Apoptotic cell death and nitric oxide: activating and antagonistic transducing pathways","volume":"63","author":"Brune","year":"1998","journal-title":"Biochemistry (Mosc)"},{"key":"10.1016\/j.jconrel.2011.09.069_bb0555","first-page":"28","article-title":"The unique role of nitric oxide as a signaling molecule in the cardiovascular system","volume":"1","author":"Ignarro","year":"2000","journal-title":"Ital. Heart J."},{"key":"10.1016\/j.jconrel.2011.09.069_bb0560","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1146\/annurev.pharmtox.44.101802.121646","article-title":"Biochemical mechanism of nitroglycerin action and tolerance: is this old mystery solved?","volume":"44","author":"Fung","year":"2004","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"2","key":"10.1016\/j.jconrel.2011.09.069_bb0565","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1042\/bst0210330","article-title":"Pathological implications of nitric oxide, superoxide and peroxynitrite formation","volume":"21","author":"Beckman","year":"1993","journal-title":"Biochem. Soc. Trans."},{"issue":"6","key":"10.1016\/j.jconrel.2011.09.069_bb0570","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/00007890-199909270-00013","article-title":"Beneficial effects of inducible nitric oxide synthase inhibitor on reperfusion injury in the pig liver","volume":"68","author":"Isobe","year":"1999","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.jconrel.2011.09.069_bb0575","doi-asserted-by":"crossref","first-page":"308","DOI":"10.2133\/dmpk.24.308","article-title":"Albumin as a nitric oxide-traffic protein: characterization, biochemistry and possible future therapeutic applications","volume":"24","author":"Ishima","year":"2009","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.jconrel.2011.09.069_bb0580","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10715760000300011","article-title":"A chemiluminescense-based assay for S-nitrosoalbumin and other plasma S-nitrosothiols","volume":"32","author":"Marley","year":"2000","journal-title":"Free Radic. Res."},{"issue":"3","key":"10.1016\/j.jconrel.2011.09.069_bb0585","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2174\/187152507781058735","article-title":"Development of nitric oxide donors for the treatment of cardiovascular diseases","volume":"5","author":"Katsumi","year":"2007","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"issue":"25","key":"10.1016\/j.jconrel.2011.09.069_bb0590","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1161\/01.CIR.0000018745.11739.9B","article-title":"S-nitroso human serum albumin treatment reduces ischemia\/reperfusion injury in skeletal muscle via nitric oxide release","volume":"105","author":"Hallstrom","year":"2002","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jconrel.2011.09.069_bb0595","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000079139","article-title":"S-nitroso human serum albumin improves oxygen metabolism during reperfusion after severe myocardial ischemia","volume":"72","author":"Dworschak","year":"2004","journal-title":"Pharmacology"},{"issue":"50","key":"10.1016\/j.jconrel.2011.09.069_bb0600","doi-asserted-by":"crossref","first-page":"34966","DOI":"10.1074\/jbc.M807009200","article-title":"S-nitrosylated human serum albumin-mediated cytoprotective activity is enhanced by fatty acid binding","volume":"283","author":"Ishima","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.jconrel.2011.09.069_bb0605","doi-asserted-by":"crossref","first-page":"L1179","DOI":"10.1152\/ajplung.00242.2003","article-title":"Caveolin regulation of endothelial function","volume":"285","author":"Minshall","year":"2003","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"issue":"8","key":"10.1016\/j.jconrel.2011.09.069_bb0610","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc1412","article-title":"Pathways of apoptotic and non-apoptotic death in tumour cells","volume":"4","author":"Okada","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.jconrel.2011.09.069_bb0615","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ceb.2006.10.008","article-title":"Apoptosis in the treatment of cancer: a promise kept?","volume":"18","author":"Meng","year":"2006","journal-title":"Curr. Opin. Cell Biol."},{"issue":"16","key":"10.1016\/j.jconrel.2011.09.069_bb0620","doi-asserted-by":"crossref","first-page":"7674","DOI":"10.1073\/pnas.89.16.7674","article-title":"Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin","volume":"89","author":"Stamler","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"1","key":"10.1016\/j.jconrel.2011.09.069_bb0625","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1124\/jpet.107.132100","article-title":"Design and evaluation of S-nitrosylated human serum albumin as a novel anticancer drug","volume":"325","author":"Katayama","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.jconrel.2011.09.069_bb0630","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.niox.2009.09.003","article-title":"Nitrosylated human serum albumin (SNO-HSA) induces apoptosis in tumor cells","volume":"22","author":"Katayama","year":"2010","journal-title":"Nitric Oxide"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2011.09.069_bb0635","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cccn.2004.06.013","article-title":"Structural analysis and fatty acid-binding properties of two Croatian variants of human serum albumin","volume":"349","author":"Kragh-Hansen","year":"2004","journal-title":"Clin. Chim. Acta"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2011.09.069_bb0640","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1046\/j.1432-1327.1998.2510329.x","article-title":"Structural characterization of three genetic variants of human serum albumin modified in subdomains IIB and IIIA","volume":"251","author":"Galliano","year":"1998","journal-title":"Eur. J. Biochem."},{"issue":"3","key":"10.1016\/j.jconrel.2011.09.069_bb0645","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1124\/jpet.106.114959","article-title":"S-Nitrosylation of human variant albumin Liprizzi (R410C) confers potent antibacterial and cytoprotective properties","volume":"320","author":"Ishima","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365911008546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365911008546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:27:01Z","timestamp":1759159621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365911008546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":129,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0168365911008546"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2011.09.069","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of albumin on drug delivery \u2014 New applications on the horizon","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2011.09.069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}